University of Georgia Research Foundation, Inc and Emory University v Biochem Pharma, Inc

The Federal Court of Australia considered a dispute between the University of Georgia Research Foundation, Inc and Emory University (collectively referred to as "the plaintiffs") and Biochem Pharma, Inc, relating to patents for a method of treatment of HIV infection using an enantiomerically pure b-D-dioxolanyl nucleoside. The plaintiffs claimed that Biochem Pharma, Inc had infringed their patents through the manufacture and sale of a pharmaceutical composition containing the specified nucleoside. The dispute required the court to determine whether Biochem Pharma, Inc's products indeed infringed the patents in question.

The primary legal issue before the court was whether the claims of the patents were valid and, if so, whether Biochem Pharma, Inc's products fell within the scope of those claims. The court had to scrutinise the patent specifications, interpret the claims, and compare them with the accused products. A significant aspect of the analysis involved understanding the chemical structure and properties of the b-D-dioxolanyl nucleoside and its enantiomerically pure form, and how these related to the claims made in the patents.

In its decision, the court found that the claims in the patents were valid and that Biochem Pharma, Inc's products did indeed fall within the scope of these claims. The court's reasoning hinged on the detailed analysis of the chemical specifications and the comparison with the accused products. The court concluded that the enantiomerically pure b-D-dioxolanyl nucleoside, as described in the patents, was present in Biochem Pharma, Inc's products, thus constituting an infringement of the patents. Consequently, the court ruled in favour of the plaintiffs, finding that Biochem Pharma, Inc had infringed the patents.

As a result of the decision, the court ordered Biochem Pharma, Inc to cease the manufacture and sale of the infringing products and to pay damages to the plaintiffs for the infringement of their patents. The court also issued an injunction preventing Biochem Pharma, Inc from continuing to infringe the patents in the future. This decision underscores the importance of careful patent drafting and the stringent requirements for establishing patent infringement in Australia.